BioMarin Pharmaceutical Inc.
BMRN
$53.81
-$0.50-0.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.39% | 18.36% | 19.36% | 17.97% | 19.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.39% | 18.36% | 19.36% | 17.97% | 19.14% |
| Cost of Revenue | -7.51% | 3.94% | 4.98% | 9.96% | -6.96% |
| Gross Profit | 23.24% | 26.18% | 27.66% | 22.56% | 40.63% |
| SG&A Expenses | -3.83% | -1.62% | 7.95% | 11.97% | 17.10% |
| Depreciation & Amortization | -50.47% | -59.08% | -44.43% | -30.47% | -22.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.32% | -2.32% | 2.24% | 6.11% | 12.07% |
| Operating Income | 83.87% | 206.14% | 211.88% | 160.56% | 115.80% |
| Income Before Tax | 73.53% | 181.25% | 184.09% | 187.31% | 158.08% |
| Income Tax Expenses | 129.69% | 334.30% | 371.57% | 449.31% | 1,385.08% |
| Earnings from Continuing Operations | 61.47% | 156.15% | 154.99% | 154.62% | 119.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.47% | 156.15% | 154.99% | 154.62% | 119.21% |
| EBIT | 83.87% | 206.14% | 211.88% | 160.56% | 115.80% |
| EBITDA | 61.01% | 139.39% | 134.62% | 100.05% | 69.35% |
| EPS Basic | 60.21% | 153.60% | 152.09% | 151.39% | 116.68% |
| Normalized Basic EPS | 79.31% | 191.55% | 197.41% | 165.53% | 100.43% |
| EPS Diluted | 62.63% | 158.99% | 157.25% | 157.15% | 117.91% |
| Normalized Diluted EPS | 82.12% | 196.31% | 198.40% | 163.07% | 97.92% |
| Average Basic Shares Outstanding | 1.02% | 1.10% | 1.15% | 1.17% | 1.21% |
| Average Diluted Shares Outstanding | -0.83% | 0.58% | 1.73% | 2.73% | 2.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |